WuXi PharmaTech Shares Popped: What You Need to Know (WX)

WuXi PharmaTech Shares Popped: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of WuXi PharmaTech (NYSE: WX ) have popped by as much as 12% today on news that the company has acquired Abgent, a provider of biological research reagent products and services.

So what: Abgent is one of the world’s largest makers of antibody reagents used for research purposes. The company offers a broad range of roughly 20,000 products. No financial details were disclosed about the acquisition, but Abgent will bring new product lines to WuXi for drug discovery and basic research.

Now what: WuXi CEO Dr. Ge Li said, “WuXi’s acquisition of Abgent continues our strategy leveraging the advantages of our China-based operations.” The company’s goal is to build a platform that allows any person or company to discover and develop drugs more efficiently and cost effectively. WuXi will incorporate Abgent’s integrated development and production platform to better penetrate the global research reagent market.

Interested in more info on WuXi PharmaTech? Add it to your watchlist by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.